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INTRODUCTION
Cytochrome P450s (CYPs) are heme-thiolate enzymes whose carbon monoxide-bound forms have peak spectral absorbances of 450 nm. Two-thirds of the human CYP gene superfamily are important in the biosynthesis or catabolism of endogenous substances such as steroid hormones, sterols, and fatty acids. The other third are involved in metabolism of xenobiotics, and most of them are mainly expressed in liver. However, a subset of CYPs are also expressed to some degree in extra-hepatic tissues (Ding and Kaminsky, 2003) . Cancer cells also express various CYP enzymes (Rooney et al., 2004) . The enzyme activities and the expression levels of many CYPs are down-regulated during inflammation and infection, causing decreased metabolic clearance of CYP substrates, elevation of plasma drug levels, and drug toxicity (Aitken et al., 2006) . Proinflammatory cytokine treatments of primary human and rodent hepatocytes recapitulate many of the in vivo effects of inflammation of hepatic CYP enzymes (Aitken et al., 2006; Aitken and Morgan, 2007) .
Nitric oxide, NO is a short-lived cellular messenger with important roles in cell signaling.
Inducible NO synthase (iNOS, NOS2) is induced during infection and inflammation via nuclear factor kappa B (NFκB) activation, and NFκB activation is dependent on proteasomal activity (Palombella et al., 1994) . Bacterial endotoxin (LPS) or certain proinflammatory cytokine treatments cause NOS2 induction and NO production in vivo and in cultures of various cell lines (Geller et al., 1994) . We reported that CYP2B1 is down-regulated in primary cultures of rat hepatocytes by two independent mechanisms in response to LPS: NO-independent mRNA suppression at lower concentrations, and NO-dependent protein suppression at higher This article has not been copyedited and formatted. The final version may differ from this version. (Ferrari et al., 2001 ). More recently we discovered that NO-dependent CYP2B1 degradation proceeds via polyubiquitination and the proteasomal degradation pathway .
While the transcriptional regulation of CYP genes by inflammatory factors has been relatively well-characterized, posttranscriptional regulation of CYP proteins is less well understood. Therefore, the purpose of this study was to identify other hepatic proteins that undergo NO-dependent degradation in a manner similar to that which we described for CYP2B
proteins . Using the iTRAQ-based proteomic approach (Zieske, 2006) , we identified CYP3A1 as a protein whose levels were increased in hepatocytes treated with interleukin (IL)-1β plus the NOS inhibitor NMA, compared to hepatocytes treated with IL-1β alone. Subsequent experiments revealed that CYP3A protein, like CYP2B proteins, undergoes NO-and proteasome-dependent degradation in response to IL-1β treatment in PB-treated rat hepatocytes. However, these studies also revealed a slower mechanism of post-transcriptional down-regulation of CYP3A by , that is both NO-and proteasome-independent. This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS
Materials and Reagents.
Interleukin (IL)-1β and IL-6 were purchased from R&D systems Rat Hepatocyte Isolation and Treatment. Rat hepatocytes were isolated by a two-step in situ collagenase perfusion procedure as previously described . After male Sprague-Dawley rats (230-280 g) were anesthetized by ketamine/xylazine solution, the liver was perfused with Krebs-Ringer bicarbonate buffer and then with 0.3 mg/ml collagenase type IV for 10 min. Cells were plated on collagen plates with plating medium containing 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA) and three hours later, cells were overlaid with new medium containing Matrigel (0.23 mg/ml, BD Biosciences, San Jose, CA). Next day, the medium was changed to CYP2B1 medium (Williams E containing 10mM Hepes pH 7.4, 10 nM insulin, 25 nM
Dex and 10mg/ml Pen/Strep). Cultures were maintained for 6 to 7 days at 37°C in 5% CO 2 with regular media changes. Beginning on day 4, cells were treated for 2 days with 1 mM PB to induce This article has not been copyedited and formatted. The final version may differ from this version. CYP3A expression, and PB was present for the rest of the experiment. At the conclusion of the experiment, media were removed and reserved for NO assay by the Griess reaction .
Protein Extraction and Immunoblotting. Hepatocytes were harvested with a cell scraper, after which the cells were incubated on the ice in phosphate buffered saline (PBS) with 1 mM EDTA for at least 20 min to remove Matrigel, and then were collected by centrifugation at 1000g for 5 min.
To extract total protein, cells in lysis buffer (50 mM Tris, pH7.5; 0.1% SDS; 0.5% NP40; 1 mM EDTA; protease inhibitor cocktail, Sigma) were sonicated briefly for 10 sec and then centrifuged for 10 min at 11,000 g. The supernatant (total cell lysate) was used for SDS-PAGE and immunoblotting. SDS-PAGE and Western blotting were carried out as described previously (Ferrari et al., 2001 ). Anti-CYP2B1 antibody, (diluted 1:20,000) and anti-CYP3A2 antibody (diluted 1:10,000) were incubated overnight at 4 °C and then horseradish peroxidase (HRP)-conjugated secondary antibody was incubated for 1 hr at room-temperature. Chemiluminescence was detected with ECL substrate (Pierce Biotech) on X-ray film. The protein loads used in the Western blot assays were chosen to be within the range that gave a linear correlation of band densities with amount of applied antigen, as determined in optimization experiments. The intensities of bands were measured by densitometry and Kodak imaging software.
iTRAQ-based scan for NO-regulated proteins Four-day old primary rat hepatocytes cultured on 150 mm plates were treated for two days with 1 mM PB and then treated with 5 ng/ml IL-1β or IL-1β + NMA (300 μM) in the continued presence of PB for 9 hours. Total cell lysates were prepared as described above, except that an additional wash step with PBS/EDTA was included to remove Master Mix (Applied Biosystems) using ABI 7300 RT-PCR equipment. Glyceraldehyde 3-phosphatase dehydrogenase (GAPDH) mRNA was used as the normalization control. The primers described by Hoen et al (2000) were used for CYP3A isoform measurements by real-time PCR:
The GAPDH primers used were TTCAACGGCACAGTCAAG and CACACCCATCACAAACAT. Analysis of real-time PCR were carried out by the ΔΔ Ct method (Livak and Schmittgen, 2001 ).
Cellular CYP3A Activity Assay. CYP3A activity was assayed by using the P450-Glo To identify proteins whose levels are rapidly affected by NO in response to cytokines, primary hepatocytes were treated with IL-1β or IL-1β plus the NOS inhibitor ΝΜΑ for 9 h, and total cell lysates were used for iTRAQ analysis. Proteins whose levels differ in the two groups are candidates for being regulated by cellularly generated NO. From the iTRAQ data we identified 229 proteins at a confidence level of 95% (data not shown). We then searched for proteins whose abundance differed between the two samples. One such protein was CYP2B, which is known to be regulated by NO . Its relative abundance, calculated from the peptides FSLATMR and YFPGAHR (contained in both CYP2B1 and 2B2), was increased by a factor of 1.6
by NMA treatment (data not shown). Another protein identified in this manner was CYP3A1
( Fig. 1) . Peptides ALLSPTFTSGR (CYP3A1 and 3A2 specific) and GSVVMIPSYALHR This article has not been copyedited and formatted. The final version may differ from this version. 12 (CYP3A1 specific) were identified and assigned to CYP3A1. The mass chromatograms for these peptides are shown in Fig. 1 , in which the samples labeled with the higher mass tags (116 and 117;
corresponding to cells treated with IL-1β + NMA) were almost twice as abundant as those labeled with the lower mass tags (114 and 115; IL-1β alone). These data suggested that CYP3A1 might be down-regulated by NO.
CYP3A expression in PB-treated rat hepatocytes. Because the proteomic scan identified CYP3A1 as a protein likely to be regulated by NO, we examined in detail the CYP3A1 regulation by NO in the primary cultures. In the rat, five CYP3A isoforms have been identified (Hoen et al., 2000) : CYP3A1, 3A2, 3A9, 3A18, and 3A23. However CYP3A23 encodes active CYP3A1
protein and was suggested to be the same gene (Hoen et al., 2000) . CYP3A1 and 3A2, the major rat liver isoforms of CYP3A, are inducible via pregnane X receptor (PXR) and/or constitutive androstane receptor (CAR) activation (Guengerich, 1999) . In cultured primary hepatocytes without an inducer, it was difficult to detect CYP3A protein in total cell lysates by immunoblotting ( Fig. 2A) . Therefore, to study the down-regulation of CYP3A proteins, we treated primary hepatocytes with 1 mM PB for 2 days to induce CYP3A mRNAs and proteins. Several studies have reported CYP3A regulation by PB treatments in rat primary cultures (Brown et al., 1997; Joannard et al., 2000) , but the effect of PB on all four rat isoforms of CYP3A has not been reported in these cultures. CYP3A protein expression was greatly enhanced by PB treatment ( Fig.   2A ). In our system, CYP3A9 was not detectable in control or PB treated samples. CYP3A2
showed the highest fold increase (285-fold) by PB treatment (Fig. 2B) , followed by CYP3A1 (98-fold) and CYP3A18 (14-fold). Even though CYP3A2 mRNA showed the highest fold increase, the absolute Ct values indicated that CYP3A1 mRNA was 100-fold and 18-fold more abundant This article has not been copyedited and formatted. The final version may differ from this version. 13 than CYP3A2 and CYP3A18, respectively, in the PB-treated cells (Supp. Fig. 1A ). Based on the Ct values and our iTRAQ data, we suggest that the CYP3A protein we detect in the PB-treated primary cultures is CYP3A1, even allowing for possible small differences in amplification of the different 3A transcripts in the PCR reaction. CYP3A activity in live cultures was measured using the P-450 Glo® assay system with luciferin-PPXE as a CYP3A substrate. Although the specificity of this substrate for rat CYP3A proteins has not been proven, PB treatment of the cells resulted in about a 20-fold increase in CYP3A activity (Suppl Fig. 1B) , which is well correlated with CYP3A protein level.
Post-transcriptional Down-regulation of CYP3A. Rat hepatocytes treated with PB for 2 days were stimulated with IL-1β for various times. Hepatocyte CYP3A protein levels started to decline within 6 h to 40% of control level, and continued to decline to 20% of control levels at 24 h, while the mRNA of CYP3A1 was not significantly affected at any time point (Fig. 3A & B) . NO 2 and NO 3 (NOx) species were detectable in culture medium within 6 h and achieved their maximum levels at 24 h (Suppl. Fig. 2A ). The data demonstrate that CYP3A protein is down-regulated posttranscriptionally by IL-1β stimulation, since protein down-regulation occurs prior to mRNA downregulation.
IL-6 is another proinflammatory cytokine known to regulate CYP expression, which does not induce NOS2. Treatment of hepatocytes with IL-1β, but not IL-6, stimulated NO production (Suppl Fig. 2B ). In agreement with our previous findings , CYP2B proteins were down-regulated only in IL-1β stimulated cells or IL-1β and IL-6 co-treated samples which were producing NOx in the culture media (Fig. 4A) . In sharp contrast, CYP3A protein was downThis article has not been copyedited and formatted. The final version may differ from this version. 14 regulated by both cytokines, (Fig. 4A ) although their effects were not additive. CYP2B1 or CYP3A1 mRNAs were not down-regulated within 18 h of any treatment (Fig. 4A ). IL-6 treatment did not down-regulate CYP3A protein within 9 h, but resulted in CYP3A downregulation to 25% of control at 24 h (Fig. 4B) .
NO-dependent and NO-independent CYP3A Down-regulation. To confirm our iTRAQ data suggesting that CYP3A1 is an NO-regulated protein, primary hepatocytes were treated with IL-1β
for 9 or 24 h with or without the NOS inhibitor NMA. NMA (100 μM) treatment resulted in blockade of NO production in media (data not shown). As shown previously , IL-1β-stimulated CYP2B down-regulation was prevented by NMA treatment at both 9 and 24 h (Fig.   5 ). IL-1β stimulation caused CYP3A down-regulation to less than 30% of control at 24 h: this down-regulation was not blocked by NMA co-treatment and is therefore NO-independent (Fig. 5 ).
However at 9 h CYP3A was down-regulated by IL-1β to 40% of control levels and this downregulation was partially inhibited by NMA co-treatment (Fig. 5) , demonstrating that IL-1β-stimulated CYP3A down-regulation is at least partially NO-dependent at earlier time points.
Other NOS inhibitors. L-NIL or L-NAME (100 μM each) each effectively blocked NO production, and also blocked the down-regulation of CYP3A protein caused by 9 h of IL-1β-stimulation (Suppl Fig. 3) . Furthermore, treatment with the chemical NO donors, GSNO and NOC-18 mimicked the cellular effect of NO, resulting in 50% down-regulation of CYP3A protein within 8 h in the primary hepatocytes (Suppl. Fig. 4 ). Taken together, our data indicate that IL-1β-stimulated CYP3A down-regulation is NO-dependent at earlier time points (9 h), but not at later times (24 h).
This article has not been copyedited and formatted. The final version may differ from this version. We also measured CYP3A activity in the cultures using luciferin-PPXE. IL-1β stimulation in the hepatocytes resulted in down regulation of CYP3A activity to 35% and 22% of control within 9 and 24 h, respectively (Suppl. Fig. 5 ). These data are well correlated with the above data on CYP3A protein levels, suggesting that protein down-regulation is causing the reduced CYP3A activity in the hepatocytes (with the caveat that this substrate may not be specific for CYP3As in rat).
Proteasome-dependent and -independent down-regulation of CYP3A. We previously showed that NO-dependent CYP2B down-regulation occurs via proteasomal degradation .
Therefore, we examined whether or not NO-dependent CYP3A down-regulation is proteasome dependent. In a control experiment, we ascertained that MG132, a proteasome inhibitor, effectively inhibited CYP3A degradation caused by the suicide substrate DDEP (Suppl Fig 6A) ( Wang et al., 1999) . We also determined that that MG132 effectively blocked the proteasome activity in our cultures, using Suc-LLVY-luciferin as a proteasome substrate. (Suppl. Fig. 6B ).
Next, we stimulated the hepatocytes with IL-1β to allow for NO production, and added MG132 three hours later. Cells were harvested 9 h after IL-1β treatments for measurement of CYP3A protein levels. This three hour delay in MG132 treatment is necessary because NOS2 induction requires proteasome activity for its transcriptional activation via NF-κB. As shown previously , this design permitted NO production to a level that was 60 % of that of cells treated with IL-1β alone (Fig. 6A ). MG132 treatment completely blocked IL-1β-evoked down-regulation of CYP3A (Fig. 6A) 16 donor NOC-18 (500 μM) resulted in the down-regulation of CYP3A to 25% of control levels , and this was blocked by co-treatment with bortezomib ( Fig. 6B) , a proteasome inhibitor used to treat cancer patients with multiple myeloma. Bortezomib effectively inhibited proteasome activity in the hepatocyte cultures (Suppl. Fig. 6B ). Taken together, our data demonstrate that NO-evoked CYP3A down-regulation is proteasome dependent.
We then examined whether the NO-independent (slower) down-regulation of CYP3A by IL-1β is proteasome-dependent. PB-treated primary hepatocytes were treated for 24 h with IL-1β
with or without addition (3 h delay) of the proteasome inhibitors, MG132 and gliotoxin. NOx production in cells receiving the delayed proteasome inhibitor treatment was only about half of that with IL-1β alone (Fig. 7A ), but this may not be important because in this experiment we are studying an NO-independent mechanism. IL-1β treatment resulted in the down-regulation of CYP2B and CYP3A (Fig. 7A) . The down-regulation of CYP2B, which is NO-dependent even at 24 h, was completely blocked by the proteasome inhibitors, MG132 and gliotoxin. However, CYP3A down-regulation was not blocked by these treatments (Fig. 7A) , suggesting that NOindependent CYP3A down-regulation is also proteasome-independent. E64-d, a membrane permeable calpain inhibitor, did not inhibit the IL-1β evoked CYP2B down-regulation (Fig. 7A) .
Although E64-d alone suppressed the expression level of CYP3A protein to some extent, IL-1β-stimulated CYP3A down-regulation was partially inhibited by E64-d treatment, suggesting that calpain might be involved in the NO-independent down-regulation of CYP3A by cytokines. The NO-independent down-regulation of CYP3A proteins by IL-6 is also proteasome-independent, because it was not blocked by bortezomib (10 μM) co-treatment (Fig. 7B ).
This article has not been copyedited and formatted. The final version may differ from this version. CYP3A by slower post-transcriptional pathways that are not blocked by NOS inhibitors. This NOindependent CYP3A down-regulation by IL-1β or IL-6 was also insensitive to proteasome inhibitors. This was not due to a lack of efficacy of the inhibitors, because CYP2B downregulation was blocked. Thus, CYP3A protein exhibits novel dual regulation mechanisms by cytokines.
How cellular NO can trigger the degradation of CYP3As remains to be determined.
Proteasome-dependent degradation stimulated by cellular NOS-derived NO, or chemical NO donors, has been reported for several other proteins, e.g. neutral ceramidase in rat renal mesangial cells (Franzen et al., 2002) , iron regulatory protein-2 (IRP2) in RAW 264.7 cells (Kim et al., 2004) , and insulin receptor substrate-1 in murine myotubes (Sugita et al., 2005) .
NO (or reactive
This article has not been copyedited and formatted. The final version may differ from this version. nitrogen species) also can modify amino acid residues, cysteine or tyrosine, of proteins by Snitrosylation and tyrosine nitration. Moreover, S-nitrosylation of IRP2 triggers its polyubiquitination proteasomal degradation, and mutation of cysteine (C178S) of IRP2 prevents NOmediated degradation (Kim et al., 2004) . We showed that CYP2B1 can be S-nitrosylated by GSNO treatment in vitro and that this treatment increases poly-ubiquitination of the protein . We have confirmed that CYP3A can also be S-nitrosylated by GSNO treatment in vitro (not shown). It is not clear yet how NO can stimulate proteasome-dependent protein down-regulation of CYP, but we speculate that S-nitrosylation or tyrosine nitration of CYP3A1 and CYP2B1, like IRP2, is necessary for their recognition by specific ubiquitin E3 ligases that target them for proteasomal degradation. However, NO can bind cytochrome P450 heme reversibly and irreversibly (Wink et al., 1993) , and Hollenberg's laboratory showed that tyrosines of CYP2B1
and CYP2E1 and heme of CYP2B1 are modified in vitro by peroxynitrite treatment, resulting in reduced activity of CYP2B1, but not CYP2E1 (Lin et al., 2007) . These modifications also deserve mechanistic interrogation for their roles in CYP degradation.
However, unlike CYP2B1, CYP3A is degraded by a second, novel proteasome-and NOindependent mechanism. Both cytokines IL-1 and IL-6 treatments showed CYP3A downregulation that was not blocked by proteasome inhibitors. We are currently working to elucidate the common downstream mechanisms that are responsible for the down-regulation. The observation that CYP3A degradation was attenuated by a calpain inhibitor deserves further study 19 degradation (ERAD) pathway in primary rat hepatocytes (Wang et al., 1999; Correia et al., 2005; Faouzi et al., 2007) . However, our observation of a proteasome-independent down-regulation by cytokines was not due to a lack of efficacy of proteasome inhibition, because CYP2B1 degradation was clearly inhibited in the same cultures, and we showed that rapid DDEP-mediated CYP3A
down-regulation was suppressed by MG132 in our cells. Cells co-treated with IL-6 and bortezomib showed a higher level of CYP3A compared to the IL-6 alone treated sample, but the difference was not significant (P<0.05) statistically. This tendency might reflect the degradation of the native CYP3A through the proteasomal pathway. findings, our data also showed that CYP3A levels were slightly suppressed by 24 h of proteasome inhibitor treatments alone, such as MG132 and gliotoxin (Fig. 7A) , and bortezomib (Fig. 7B) . The reason why these agents affect CYP3A and not CYP2B enzymes is not known. Similarly, we do not know how NMA alone down-regulates CYP3A protein after 24 h in culture (Fig. 5) .
Nevertheless, no effect of NMA or the other inhibitors L-NAME and NIL on CYP3A protein occurred at 9h, when these agents blocked down-regulation by IL-1β.
If CYP3A degradation is NO-dependent at early time points after IL-1β stimulation, how does it later become NO-independent? NOx measurement by the Griess reagent represents accumulation of NO 2 plus NO 3 in the media. We found that NOx started to be detected within 6 h, This article has not been copyedited and formatted. The final version may differ from this version. and continuously accumulated up to 24 h, but the rate of accumulation was reduced after 18 h (data not shown), suggesting the actual NO radical production by NOS2 in the culture by IL-1β stimulation peaks at earlier time points. Thus, we hypothesize that CYP3A is degraded via the NO-dependent pathway when NO radicals are produced at higher rates (earlier time point, within 9 h) and then the degradation signal is changed to the NO-independent mode when the NO radical production is reduced and cells produce anti-oxidants such as glutathione (GSH) and thioredoxin (Haendeler et al., 2004) to maintain homeostasis in the cell. That both proteasomal and calpain pathways can participate in the degradation of the same protein, and that degradation pathways can change under different conditions has been shown for several proteins, e.g. hypoxia-inducible factor 1α (Zhou et al., 2006) , c-Fos, c-Jun and p53 (Salvat et al., 1999) .
Hepatic CYP3A enzymes are down-regulated by infection and inflammation in vivo. LPS injection caused the down-regulation of CYP3A1 mRNA by 80% in rat liver (Fang et al., 2004) .
We also reported that LPS injection down-regulated CYP3A2 mRNA more rapidly than CYP3A protein in rat liver (Sewer and Morgan, 1998) , and these effects were not blocked by the NOS inhibitor aminoguanidine. This is in apparent opposition to the results we present here. The model we used, of primary rat hepatocytes cultured with Matrigel, is accepted as the best cell model to study CYP regulation in rat liver, and dexamethasone-treated hepatocytes have been employed to demonstrate the proteasome-dependent degradation of native and inhibitor-modified CYP3As (Faouzi et al., 2007) . The reported down-regulation of CYP3A1 and CYP3A2 mRNAs in vivo could reflect direct effects of LPS and/or additive or synergistic effects of cytokines in vivo. The NO-independent down-regulation of CYP3A mRNAs in vivo could be obscuring the NO-dependent down-regulation of the protein. In any case, the lack of effect of the cytokines on This article has not been copyedited and formatted. The final version may differ from this version. background. This allowed us to validate the iTRAQ approach for identification of proteins regulated in a specific way, and to uncover a novel proteasome-independent mode of CYP3A regulation as well. Interestingly, in the absence of cytokine stimulation the levels of CYP3A protein tended to increase in the cultures during the 24 h after the medium change, whereas CYP3A1 mRNA declined slightly. The reason for this is unclear, but it may reflect different stabilities of the CYP3A proteins and mRNAs.
The relevance of these findings to human CYP3As is uncertain. CYP3A4 mRNA is down-regulated by proinflammatory cytokine treatments in primary human hepatocytes (Aitken and Morgan, 2007; Aitken et al., 2008) , but neither its mRNA or protein down-regulation are NOdependent. The NO-responsiveness of human CYPS 3A5 and 3A7 remains to be determined.
In summary, we have validated iTRAQ technology as an approach to study multiple hepatocyte proteins regulated by similar pathways in hepatocytes, and thereby we demonstrated that NO-regulated proteasomal degradation of CYP proteins is not limited to CYP2B1, but also pertains to CYP3A proteins as well. Moreover, the mechanism of cytokine-evoked degradation of rat CYP3As undergoes a temporal switch from NO-and proteasome-dependent to NO-and proteasome-independent. Our results suggest that yet more CYP enzymes, involved in metabolism of drugs or physiological substrates, may undergo NO-dependent degradation during inflammatory disease states or treatment with NO-releasing drugs, with obvious consequences for drug efficacy and/or toxicity.
This article has not been copyedited and formatted. The final version may differ from this version. 
